Emyria Appoints Expert Neuropharmacologist for MDMA Program
Released
Released
Announcement PDF
ASX Announcement
20/08/2021
Emyria appoints expert neuropharmacologist for
MDMA-analogue development program
Highlights:
●
Emyria has engaged renowned neuropharmacologist, and former Head of
Psychopharmacology at UWA, Dr. Mat Martin-Iverson to help evaluate a library of
novel MDMA-analogues, recently optioned to Emyria exclusively
●
Dr. Martin-Iverson has over 35 years of experience studying amphetamines and other
psychostimulants
●
Dr. Martin-Iverson will assist in the screening of the existing library and help advise in
the creation of new compounds to help expand the library
●
Emyria’s MDMA-analogue program has the potential to result in the
commercialisation of multiple novel psychedelic-assisted therapies and treatments for
other neurological disorders
Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and
care delivery company, has engaged world-leading neuropharmacologist, Dr. Mat
Martin-Iverson to advise over the screening and expansion of Emyria’s recently announced
MDMA-analogue program. (See announcement 05 August 2021)
Dr. Martin-Iverson has over 35 years of experience studying and researching the effects of
amphetamines and other psychostimulants. Dr. Martin-Iverson has authored over 160
publications with a particular focus on dopamine-related effects including its role in drug
addiction, schizophrenia, Parkinson’s disease, attention and motivation.
Notable career highlights::
●
●
●
●
●
Former Head of Psychopharmacology Laboratory, School of Biomedical Sciences,
University of Western Australia
Professor or Associate Professor at UWA since 1995
Head of Pharmacology 2004-2006; 2016-Jan 2021
Consultant Pharmacologist, Statewide Department of Neurophysiology (Graylands
Hospital) North Metropolitan Health Services - Mental Health, 2002-2017
Member of the WA Psychotropic Advisory Committee to the Chief Psychiatrist and
WATAG from 2004-2019
1
Emyria’s Managing Director, Dr. Michael Winlo, said: “We are delighted to be working
closely with Dr. Martin-Iverson as we evaluate and expand our unique library of
MDMA-analogues.
We believe Dr. Martin-Iverson's unique expertise and deep knowledge of amphetamines
will help us identify promising compounds, as well as to design new ones, to develop
promising novel psychedelics and new treatments for neurological disorders.”
Dr. Martin-Iverson, said: “I’m excited to work with Emyria, and Dr. Matt Piggott’s team at
UWA, to screen and expand this library of unique compounds that have the potential to
become new treatments for patients in need.”
Emyria’s MDMA discovery pipeline
Emyria recently secured exclusive rights to a library of more than 100 novel MDMA
analogues from the University of Western Australia creating a unique drug-discovery
pipeline for Emyria.
The library of compounds was developed by a highly regarded research group led by
medicinal chemist, Dr. Matt Piggott. Dr. Piggott and his team have been developing
MDMA analogues, and exploring their therapeutic potential, for more than 10 years.
As part of the initial phase of work, Emyria will screen and expand the existing library in
order to identify families of patentable compounds with the greatest promise as new
psychedelic-assisted therapies and treatments for other neurological disorders.
Emyria will lead the global patent strategy, already underway, as well as further clinical
development and commercialisation of this under explored research space
Program has the potential to result in the commercialisation of multiple, novel, CNS-active
compounds to help treat patients with major unmet needs.
This announcement has been approved and authorised for release by the Managing
Director of Emyria Limited.
For further information:
Dr. Michael Winlo
Managing Director
1300 436 363
mwinlo@emyria.com
Lexi O’Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au
Andrew Williams
Media Relations
+61 (0) 412 614 125
andreww@profilemedia.com.au
2
About Emyria (www.emyria.com)
Emyria Limited is a clinical drug development and care delivery company.
Emyria’s
Treatments target large unmet needs and are focused on obtaining approval
(“registration”) with major global regulators. Emyria’s treatment development programs
are informed by insights generated from extensive analysis of Emyria Data - deep,
ethically-sourced clinical evidence that is gathered with patients across Emyria’s
independent clinical services (Emerald Clinics - www.emeraldclinics.com.au)
Emyria Data provides deep treatment insights and is therefore a source of unique IP,
strategically designed drug development and personalised care programs.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for
the Company, the company’s strategy, future operations, and other statements containing
the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar
expressions, constitute forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result of various important
factors, including: the Company’s ability to successfully develop its product candidates
and timely complete its planned clinical programs and the Company’s ability to obtain
marketing approvals for its product candidates. In addition, the forward-looking
statements included in this press release represents the Company’s views as of the date
hereof. The Company anticipates that subsequent events and developments will cause
the Company’s views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent to the date hereof.
3
Share your feedback
Discover